

Intec Pharma

Earnings report

Progress across ongoing and new clinical trials

Pharma & biotech

22 May 2017

Price **NIS18.80**
Market cap **NIS258m**

NIS3.65/US\$

Estimated net cash (\$m) at March 2017 27.2

Shares in issue 13.8m


Free float 83%

Code NTEC

Primary exchange TASE

Secondary exchange NASDAQ

Share price performance



% 1m 3m 12m

Abs (3.8) (3.3) 42.5

Rel (local) (6.1) (6.7) 34.4

52-week high/low NIS23.4 NIS12.2

Business description

Intec Pharma is a drug delivery company that has developed the accordion pill, a novel gastroretentive controlled release formulation. The company is currently using this technology to develop AP-CDLD for Parkinson's in Phase III, AP-ZP for insomnia completed Phase II, and AP-CBD/THC in Phase I for pain indications.

Next events

AP-ZP partnering discussions Ongoing

AP-CBD/THC Phase I completion Q317

AP-CDLD enrolment complete Q417

Analysts

Maxim Jacobs +1 646 653 7027

Nathaniel Calloway +1 646 653 7036

healthcare@edisongroup.com
[Edison profile page](#)

Intec Pharma has made significant progress, both with its current development programme and in new directions. The company is in a Phase III clinical trial of an accordion pill (AP) formulation of carbidopa and levodopa (AP-CDLD), and announced that it has reduced the target trial size to 328 patients (from 460) based on feedback from experts, and expects to be fully enrolled by Q417. Additionally, the company announced in March 2017 that it has started a Phase I trial expected to complete in Q317 of an AP formulation with cannabidiol and tetrahydrocannabinol (AP-CBD/THC), the two primary cannabinoids in Cannabis sativa.

Year end	Revenue (\$m)	PBT* (\$m)	EPS* (\$)	DPS (\$)	P/E (x)	Yield (%)
12/15	0.0	(7.2)	(0.92)	0.0	N/A	N/A
12/16	0.0	(13.4)	(1.17)	0.0	N/A	N/A
12/17e	0.0	(12.8)	(0.89)	0.0	N/A	N/A
12/18e	0.0	(13.6)	(0.89)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

AP-CDLD trial size down on updated assumptions

The reduction in the target enrolment for the AP-CDLD Phase III trial was made following feedback from key opinion leaders and biostatisticians, which suggested that standard deviation would be lower than initial assumptions. The new design will require only a modest improvement in data (18% better resolution, power of 0.9, assuming similar standard deviations in the arms) than the previous design. The trial is targeting full enrolment at the end of 2017 and top-line data in mid-2018.

Cannabinoid programme initiated

The company initiated a Phase I clinical trial of AP-CBD/THC to examine the pharmacokinetics, safety and tolerability of the drug in comparison to the approved sublingual CBD/THC spray Sativex. The oral bioavailability of cannabinoids is low at approximately 6% and the pharmacokinetics are somewhat unpredictable due to low solubility, but the AP is a device that can potentially address these issues. Potential target indications include neuropathic low back pain and fibromyalgia, although it has not committed to either programme yet.

Reduced financial hurdles

The company performed a private placement of 2.3m shares at \$4.40 on 10 March 2017, bringing estimated cash to \$27.2m. We expect the company will only need a further \$10m in additional financing before AP-CDLD approval in 2019.

Valuation: Increased to NIS606m

We have increased our valuation to NIS606m (~\$166m) from NIS540-582m, although the value per share has reduced to NIS44.02 (~\$12.04) from NIS47-51. The majority of this increase is due to a reduction in the clinical trial costs for AP-CDLD, offset by an increase in shares from the offering. We expect to update our valuation following the completion of the AP-CBD/THC clinical trial in Q317.

AP-CDLD trial size down

In November 2016, Intec reported that it reduced the size of its Phase III clinical programme from 460 patients to 328, a reduction of 29%. The trial is measuring the improvement in off time between patients on AP-CDLD and patients on Sinemet, a formulation of immediate release carbidopa/levodopa. The reduction in trial size was made following feedback from key opinion leaders and biostatisticians, which suggested that the predicted standard deviation for the trial was too large. Based on the stated power of 0.9, we have calculated that the reduction in patient number will require data that is 18% better resolved than in the initial trial design (assuming similar standard deviations between arms) to be statistically significant. Resolution in this context refers to the separation between the arms (delta) over the standard deviation of the arms, which the experts suggested was too large in the initial trial assumptions. This means that only a modest improvement in the standard deviation (15%) is required to justify using 132 fewer patients. The company stated that the trial should be fully enrolled in Q417, implying completion in mid-2018.

The cannabinoid programme

Intec announced in March 2017 that it has initiated a Phase I clinical trial of an AP formulation of the two primary cannabinoids in *Cannabis sativa*, cannabidiol (CBD) and tetrahydrocannabinol (THC), AP-CBD/THC. The company has announced that it intends to examine AP-CBD/THC for the treatment of “various indications, including low back pain and fibromyalgia”. The current Phase I trial is in 21 healthy volunteers and is examining the pharmacokinetics, safety and tolerability of two AP-CBD/THC formulations in comparison to Sativex. Sativex is a buccal formulation of CBD and THC developed by GW Pharmaceuticals for the treatment of spasticity associated with multiple sclerosis. Sativex is approved in 28 countries, although it is not approved in the US. The trial has a target completion date in Q317.

There are several aspects of cannabinoid pharmacology that could potentially be improved by the AP formulation. Cannabinoids have a low oral bioavailability measured at an average of 6% for THC¹ and CBD,² although with high levels of variability between individuals and doses even when administered under similar conditions. THC and CBD are very oily molecules that dissolve poorly in the aqueous gastric medium. The dissolution and absorption of the drug is aided in the gut by bile acids. One study showed a significant increase in THC bioavailability when it was co-administered with the bile acid glycocholate.³ This dependence on bile acids for absorption also explains some of the variability in bioavailability. THC will sometimes have a peak concentration at two different times due to the enterohepatic circulation of bile acids and variable absorption rates depending on their presence.⁴ The AP device is specifically designed to maximize the exposure of drugs to bile acids secreted in the upper gastrointestinal tract, and an AP-CBD/THC formulation may significantly improve the drug's oral profile. The goal of the Phase I study is to examine this profile and determine the applicability of the formulation to any future indications.

¹ Ohlsson A, et al (1980) Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. *Clin. Pharmacol. Ther.* 28, 409-16.

² Agurell S, et al. (1981). Interaction of THC with cannabiniol and cannabidiol following oral administration in man. Assay of cannabiniol and cannabidiol by mass fragmentography. *Experientia* 37, 1090–2.

³ Perez-Reyes M, et al. (1973) Pharmacology of orally administered Δ^9 -tetrahydrocannabinol. *Clin. Pharmacol. Ther.* 14, 48-55.

⁴ Huestis MA, (2007) Human Cannabinoid Pharmacokinetics. *Chem. Biodivers.* 4, 1770-1804.

The two indications being pursued by the company were neuropathic low back pain and fibromyalgia, although they have made no commitments to study either. Although both of these indications can be described as pain disorders, their etiologies are significantly different. Low back pain can be mechanical in nature due to stress on the muscles or bones of the lower back, or neuropathic as in the case of sciatica, and the company has stated that it intends to focus on the neuropathic variety. Low back pain is an exceptionally common disorder, and approximately 10% of US adults have chronic low back pain (lasting over 12 weeks),⁵ and approximately 17% of cases are predominantly neuropathic in origin.⁶ Cannabinoids are well positioned for the treatment of neuropathic low back pain because there is evidence of their efficacy in neuropathic pain.⁷

Fibromyalgia is a poorly understood disorder characterized by chronic diffuse pain in multiple regions of the body. Although the cause of the disorder is not well understood, it has a high comorbidity with mood disorders and appears to be caused by a defect of the nervous system. This is evidenced by the drugs approved for the disorder, which include antidepressants such as Savella (milnacipran) or Cymbalta (duloxetine), as well as neuropathy drug Lyrica (pregabalin). The Centers for Disease Control (CDC) estimates that approximately four million adults are affected by the disorder in the US, although the prevalence of the disease varies dramatically based on the diagnostic criteria.⁸ The synthetic cannabinoid nabilone has shown efficacy in reducing the symptoms of the disease ($p < 0.02$ for pain, $p < 0.02$ for impact, $p < 0.02$ for anxiety).⁹

Valuation

We have increased our valuation to NIS606m (~\$166m) from NIS540-582m, although the value per share has reduced to NIS44.02 (~\$12.04) from NIS47-51. The company increased the total share count from 11.4m to 13.8m during the recent private placement. The biggest driving factor for the increase was the reduction in our AP-CDLD development costs and cash spent on the trial to date. This improved the negative NPV from NIS43m to NIS23m. The remaining increases were due to advancing our NPVs to year-end 2016. These were partially offset by an adjustment in the research timeline for AP-ZP to account for the lack of research spending or a partnership in H216.

We currently do not include the AP-CBD/THC programme in our valuation because the company has not announced a precise target indication for the programme. We expect to update our valuation following the release of more details. The current NPV for either of the proposed indications would be small at this time, as the clinical trial costs largely offset the commercial value at the requisite high-risk adjustment for a programme before completion of Phase I.

⁵ Freburger JK, et al. (2009) The Rising Prevalence of Chronic Low Back Pain. *J. Am. Med. Assoc. Int. Med.* 169, 251-258.

⁶ Torrance N, et al. (2006) The Epidemiology of Chronic Pain of Predominantly Neuropathic Origin. Results From a General Population Survey. *J. Pain* 7, 281-289.

⁷ Lynch ME and Campbell F (2011) Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. *Br. J. Pharmacol.* 72, 735-744.

⁸ Jones GT, et al. (2015) The Prevalence of Fibromyalgia in the General Population: A Comparison of the American College of Rheumatology 1990, 2010, and Modified 2010 Classification Criteria. *Arthritis and Rheumatology* 67, 568-575.

⁹ Skrabek RQ, et al. (2008) Nabilone for the Treatment of Pain in Fibromyalgia. *J. Pain* 9, 164-173.

Exhibit 1: Valuation of Intec Pharma

Development programme	Clinical stage	Prob. of success	Launch year	Launch pricing (\$)	Peak sales (\$m)	Patent/exclusivity protection	Royalty/margin	rNPV (NISm)
AP-CDLD, US	Phase III	60%	2019	7,700	111	2029	47%	281
AP-CDLD, Europe	Phase III	60%	2019	4,600	85	2029	40%	180
AP-CDLD development costs	Phase III							-23
AP-ZP (US and Europe)	Phase III ready	40%	2020	700	155	2028	15%	60
AP-ZP Licensing upfront	Phase III ready	30-50%	2018					33
Unallocated costs (administrative costs, etc.)								-24
Total								507
Net cash and equivalents (YE16 + offering) (\$m)								100
Total firm value (NISm)								606
Total basic shares (m)								13.8
Value per basic share (NIS)								44.02
Options (m)								0.1
Total diluted shares (m)								13.9
Value per diluted share (NIS)								43.58

Source: Intec reports, Edison Investment Research

Financials

Intec Pharma reported its FY16 results in April 2017. The company has changed accounting practices and now reports results in US dollars instead of NIS. Our forecasts now reflect this. The company reported an operating loss of \$13.8m for the year, up from \$7.6m in 2015. This increase was driven by R&D spending associated with the AP-CDLD Phase III clinical trial, with total R&D spending of \$10.7m. We have slightly decreased our 2017 R&D spending to \$9.9m (from \$11.1m) to reflect the reduction in the AP-CDLD Phase III trial size. This is partially offset by spending on the new AP-CBD/THC Phase I. The company ended 2016 with \$18.2m in cash and equivalents, which has subsequently been supplemented with a \$10m (gross) private placement (2.3m shares at \$4.40). We expect that the company will need \$10m in additional financing to bring it through approval of AP-CDLD and profitability in 2019. We include this as illustrative debt in 2018.

Exhibit 2: Financial summary

	\$'000s	2014	2015	2016	2017e	2018e
Year end 31 December		IFRS	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS						
Revenue		0	0	0	0	0
Cost of Sales		0	0	0	0	0
Gross Profit		0	0	0	0	0
Research and development		(3,409)	(4,815)	(10,749)	(9,916)	(10,332)
Selling, general & administrative		(2,609)	(2,788)	(3,097)	(3,407)	(3,747)
EBITDA		(6,369)	(8,330)	(14,513)	(13,795)	(14,551)
Operating Profit (before GW and except.)		(5,784)	(7,584)	(13,812)	(13,289)	(14,045)
Intangible Amortisation		0	0	0	0	0
Exceptionals/Other		0	0	0	0	0
Operating Profit		(5,784)	(7,584)	(13,812)	(13,289)	(14,045)
Net Interest		91	404	450	450	450
Other (change in fair value of warrants)		0	0	0	0	0
Profit Before Tax (norm)		(5,693)	(7,180)	(13,362)	(12,839)	(13,595)
Profit Before Tax (IFRS)		(5,693)	(7,180)	(13,362)	(12,839)	(13,595)
Tax		0	0	0	0	0
Deferred tax		0	0	0	0	0
Profit After Tax (norm)		(5,693)	(7,180)	(13,362)	(12,839)	(13,595)
Profit After Tax (IFRS)		(5,693)	(7,180)	(13,362)	(12,839)	(13,595)
Average Number of Shares Outstanding (m)		4.8	7.8	11.4	14.5	15.2
EPS - normalised (\$)		(1.18)	(0.92)	(1.17)	(0.89)	(0.89)
EPS - IFRS (\$)		(1.18)	(0.92)	(1.17)	(0.89)	(0.89)
Dividend per share (\$)		0.0	0.0	0.0	0.0	0.0
BALANCE SHEET						
Fixed Assets		4,397	4,076	4,047	4,042	4,058
Intangible Assets		0	0	0	0	0
Tangible Assets		4,397	4,076	4,047	4,042	4,058
Other		0	0	0	0	0
Current Assets		8,105	33,096	20,674	18,849	15,941
Stocks		0	0	0	0	0
Debtors		288	2,361	2,384	2,384	2,384
Cash		7,742	30,673	18,228	16,403	13,495
Other		75	62	62	62	62
Current Liabilities		(184)	(614)	(1,152)	(1,076)	(1,137)
Creditors		(184)	(614)	(1,152)	(1,076)	(1,137)
Short term borrowings		0	0	0	0	0
Long Term Liabilities		(1,164)	(327)	(97)	(97)	(10,097)
Long term borrowings		0	0	0	0	(10,000)
Other long term liabilities		(1,164)	(327)	(97)	(97)	(97)
Net Assets		11,154	36,231	23,472	21,718	8,765
CASH FLOW						
Operating Cash Flow		(4,751)	(7,931)	(12,005)	(11,324)	(12,386)
Net Interest		0	0	0	0	0
Tax		0	0	0	0	0
Capex		(76)	(1,384)	(482)	(501)	(521)
Acquisitions/disposals		2,865	0	206	0	0
Financing		4,682	32,452	0	10,000	0
Dividends		0	0	0	0	0
Other		(9)	13	0	0	0
Net Cash Flow		2,711	23,150	(12,281)	(1,825)	(12,908)
Opening net debt/(cash)		(5,400)	(7,742)	(30,673)	(18,228)	(16,403)
HP finance leases initiated		0	0	0	0	0
Exchange rate movements		(369)	(232)	8	0	0
Other		0	13	(172)	(0)	0
Closing net debt/(cash)		(7,742)	(30,673)	(18,228)	(16,403)	(3,495)

Source: Intec reports, Edison Investment Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt and Sydney. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

EDISON ISRAEL DISCLAIMER

Disclosure regarding the scheme to enhance the awareness of investors to public companies in the technology and biomed sectors that are listed on the Tel Aviv Stock Exchange and participate in the scheme (hereinafter respectively "the Scheme", "TASE", "Participant" and/or "Participants"). Edison Investment Research (Israel) Ltd, the Israeli subsidiary of Edison Investment Research Ltd (hereinafter respectively "Edison Israel" and "Edison"), has entered into an agreement with the TASE for the purpose of providing research analysis (hereinafter "the Agreement"), regarding the Participants and according to the Scheme (hereinafter "the Analysis" or "Analyses"). The Analysis will be distributed and published on the TASE website (Maya), Israel Security Authority (hereinafter "the ISA") website (Magna), and through various other distribution channels. The Analysis for each participant will be published at least four times a year, after publication of quarterly or annual financial reports, and shall be updated as necessary after publication of an immediate report with respect to the occurrence of a material event regarding a Participant. As set forth in the Agreement, Edison Israel is entitled to fees for providing its investment research services. The fees shall be paid by the Participants directly to the TASE, and TASE shall pay the fees directly to Edison. Subject to the terms and principals of the Agreement, the Annual fees that Edison Israel shall be entitled to for each Participant shall be in the range of \$35,000-50,000. As set forth in the Agreement and subject to its terms, the Analyses shall include a description of the Participant and its business activities, which shall inter alia relate to matters such as: shareholders; management; products; relevant intellectual property; the business environment in which the Participant operates; the Participant's standing in such an environment including current and forecasted trends; a description of past and current financial positions of the Participant; and a forecast regarding future developments in and of such a position and any other matter which in the professional view of the Edison (as defined below) should be addressed in a research report (of the nature published) and which may affect the decision of a reasonable investor contemplating an investment in the Participant's securities. To the extent it is relevant, the Analysis shall include a schedule of scientific analysis of an expert in the field of life sciences. An "equity research abstract" shall accompany each Equity Research Report, describing the main points addressed. The full scope reports and reports where the investment case has materially changed will include a thorough analysis and discussion. Short update notes, where the investment case has not materially changed, will include a summary valuation discussion. The Agreement with TASE regarding the participation of Edison in the scheme for the research analysis of public companies does not and shall not constitute an approval or consent on the part of TASE or the ISA or any other exchange on which securities of the Company are listed, or any other securities' regulatory authority which regulates the issuance of securities by the Company to the content of the Report or to the recommendation contained therein. A summary of this report is also published in the Hebrew language. In the event of any contradiction, inconsistency, discrepancy, ambiguity or variance between the English Report and the Hebrew summary of said Report, the English version shall prevail; and a note to this effect shall appear in any Hebrew summary of a Report. Edison is regulated by the Financial Conduct Authority. According to Article 12.3.2, Chapter 12 of the Conduct of Business Sourcebook, Edison, which produces or disseminates non-independent research, must ensure that it: 1) is clearly identified as a marketing communication; and 2) contains a clear and prominent statement that (or, in the case of an oral recommendation, to the effect that) it: a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research; and b) is not subject to any prohibition on dealing ahead of the dissemination of investment research. The financial promotion rules apply to non-independent research as though it were a marketing communication.

EDISON INVESTMENT RESEARCH DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2017. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.